Cargando…

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis

Detalles Bibliográficos
Autores principales:	Papadopoulou, Charalampia, Hong, Ying, Omoyinmi, Ebun, Brogan, Paul A, Eleftheriou, Despina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391598/ https://www.ncbi.nlm.nih.gov/pubmed/30715143 http://dx.doi.org/10.1093/brain/awz005

Ejemplares similares

Janus kinase 1/2 inhibition for the treatment of autoinflammation associated with heterozygous TNFAIP3 mutation
por: Mulhern, Ciara M., et al.
Publicado: (2019)

Vasculitis in a patient with mevalonate kinase deficiency (MKD): a case report
por: Omoyinmi, Ebun, et al.
Publicado: (2021)

Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis
por: Ding, Yuchuan, et al.
Publicado: (2021)

A case of Myhre syndrome mimicking juvenile scleroderma
por: Jensen, Barbara, et al.
Publicado: (2020)

Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review
por: Garg, Suchika, et al.
Publicado: (2019)

The Vasculopathy of Juvenile Dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2018)

Autoinflammation due to homozygous S208 MEFV mutation
por: Hong, Ying, et al.
Publicado: (2019)

Cutaneous Vasculitis and Digital Ischaemia Caused by Heterozygous Gain-of-Function Mutation in C3
por: Omoyinmi, Ebun, et al.
Publicado: (2018)

Case report: marfan syndrome (MFS) mimicking cutaneous vasculitis
por: Price-Kuehne, Fiona, et al.
Publicado: (2023)

Lentiviral Mediated ADA2 Gene Transfer Corrects the Defects Associated With Deficiency of Adenosine Deaminase Type 2
por: Hong, Ying, et al.
Publicado: (2022)

Juvenile dermatomyositis‐associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy
por: Agud‐Dios, Manuel, et al.
Publicado: (2022)

Moyamoya-like cerebrovascular disease in a child with a novel mutation in myosin heavy chain 11
por: Keylock, Annette, et al.
Publicado: (2018)

Cutaneous Vasculitis and Recurrent Infection Caused by Deficiency in Complement Factor I
por: Nanthapisal, Sira, et al.
Publicado: (2018)

A rapid turnaround gene panel for severe autoinflammation: Genetic results within 48 hours
por: McCreary, Dara, et al.
Publicado: (2022)

Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis
por: Wang, Zhaoling, et al.
Publicado: (2022)

Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
por: Montealegre, G, et al.
Publicado: (2015)

Mitochondrial and oxidative stress genes are differentially expressed in neutrophils of sJIA patients treated with tocilizumab: a pilot microarray study
por: Omoyinmi, Ebun, et al.
Publicado: (2016)

Development and Validation of a Targeted Next-Generation Sequencing Gene Panel for Children With Neuroinflammation
por: McCreary, Dara, et al.
Publicado: (2019)

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
por: Mayence, Annie, et al.
Publicado: (2019)

Identification of a novel monogenic autoinflammatory disease due to mutation in a mitochondrial chaperone protein in a single kindred, and cure with allogeneic haematopoietic stem cell transplantation
por: Standing, Ariane, et al.
Publicado: (2014)

Gene hunting in autoinflammation
por: Standing, Ariane, et al.
Publicado: (2013)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
por: Praveen, D., et al.
Publicado: (2020)

Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19
por: Finsterer, Josef, et al.
Publicado: (2021)

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
por: Papadopoulou, Charalampia, et al.
Publicado: (2020)

Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
por: Zhang, Junmei, et al.
Publicado: (2023)

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
por: Campanilho-Marques, Raquel, et al.
Publicado: (2020)

Secondary C1q Deficiency in Activated PI3Kδ Syndrome Type 2
por: Hong, Ying, et al.
Publicado: (2019)

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
por: Kubo, Satoshi, et al.
Publicado: (2018)

DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
por: Sonia, Chiging, et al.
Publicado: (2022)

Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection
por: Rodero, Mathieu Paul, et al.
Publicado: (2021)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Whole-Exome Sequencing Revealing Somatic NLRP3 Mosaicism in a Patient With Chronic Infantile Neurologic, Cutaneous, Articular Syndrome
por: Omoyinmi, Ebun, et al.
Publicado: (2014)

Mechanic’s Hand Heralding Relapse in an Indian Adolescent with Anti-MDA5 Positive Juvenile Dermatomyositis
por: Ganatra, Keya, et al.
Publicado: (2022)

Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ
por: Lei, Linda, et al.
Publicado: (2018)

De Novo PTEN Mutation in a Young Boy with Cutaneous Vasculitis
por: Mauro, Angela, et al.
Publicado: (2017)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

Milk of calcium: A rare manifestation of juvenile dermatomyositis
por: YILDIRIM, Deniz Gezgin, et al.
Publicado: (2020)

OA29 Blotting-based assays under-detected TIF1-gamma and NXP2 autoantibodies compared to immunoprecipitation in Juvenile Dermatomyositis cohorts
por: Nguyen, Huong D, et al.
Publicado: (2022)

Juvenile Dermatomyositis
por: Rhim, Jung Woo
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3oi4mcm6oh8fruglov0a77rg3r